Mr. Wiinberg has 20 years of senior leadership experience, currently serving as Chief Executive Officer of X+Vax Technology A.S., a biotech company committed to developing vaccines against pathogens acquired by mucosal infection such as herpes. Mr. Wiinberg previously served as Chief Executive Officer of  H. Lundbeck A.S., a global pharmaceutical company developing and marketing treatments for psychiatric and neurological disorders. His expertise encompasses serving on the boards of several other healthcare industry associations and multiple executive roles at Wyeth, one of the world’s largest research-driven pharmaceutical companies that was acquired by Pfizer in 2009.

The titles of Dr. Larry Norton, M.D. include, at Memorial Sloan Kettering, the Norna S. Sarofim Chair of Clinical Oncology, Senior Vice President in the Office of the President, Medical Director of the Evelyn H. Lauder Breast Center, and Deputy Director for Clinical and Translational Science of the NCI Cancer Center. He is also Professor of Medicine, Weill-Cornell Medical College and has adjunct appointments at the Cold Spring Harbor Laboratory and the Sloan School of Management, Massachusetts Institute of Technology. He is a co-founder in 1993 with Evelyn H. Lauder of the Breast Cancer Research Foundation and is now it’s Founding Scientific Director. Dr. Norton has served on or chaired numerous committees of the National Cancer Institute, National Institutes of Health, and the Institute of Medicine of the National Academy of Sciences and has served as President of the American Society of Clinical Oncology among other leadership roles in that and other organizations. He is also a Fellow of the American Society of Clinical Oncology, the American Association for Cancer Research Academy, and the American Academy of Arts and Sciences.

Dr. Norton has dedicated his life to the eradication of cancer by activities in medical care, laboratory and clinical research, advocacy and government. His research is broad, but he is best known for mathematical modeling in therapeutic development. He has been involved in the development of several effective agents including paclitaxel and trastuzumab. He co-invented the Norton-Simon Model of cancer growth, which has broadly influenced cancer therapy, and more recently the self-seeding concept of cancer metastasis and growth. He is an author of more than 400 published articles and many book chapters.

Among many honors, he received ASCO’s Karnofsky and Bonadonna Awards, the McGuire Lectureship at the San Antonio Breast Cancer Symposium, MSKCC’s Whitmore Award for Clinical Excellence, the Columbia University’s Gold Medal for Outstanding Achievement in Medical Research, The Cold Spring Harbor Laboratory Double Helix Award as well as the Thomson Reuters Highly Cited Researcher Certificate.

Todd Yancey, MD has over 35 years of combined clinical and industry experience. For the last 22 years he has had increasing levels of international industry team and functional leadership accountabilities with 16 years of executive (including C-Suite) leadership in Global Medical Affairs, Global Clinical Development and Global Product Commercialization. The majority of this time has been spent in roles inclusive of North America, but including accountabilities in LATAM, EMEA and Asia Pacific and spanning over one hundred markets.

Having worked full time at Amgen, Genentech, Onyx, Medivation, Clovis, BioMarin and BeiGene in numerous global biotechnology-pharma collaborations he has a track record of collaboration on myriad successful product development and product launch efforts. These include all solid tumor and the majority of hematology indications with particularly extensive experience in Immuno-Oncology.

He has had direct C-Suite level accountability for building and leading all areas of Global Medical Affairs, Clinical Development (Safety & Global Pharmacovigilance, Clinical Operations, Biometrics, Clinical Science) and New Market (ex-China APAC, LATAM, MENA, Israel, Turkey and Russia/CIS) Product Commercialization as well as Program Leadership and Alliance Management.

Dr. Stein brings over 35 years of biopharmaceutical industry, currently serving as Chief Medical Officer of Protagenic Therapeutics and Executive Vice President of Research and Development of MINDEX. He previously served as President of R&D at Agenus Inc. where he lead Agenus’ research, preclinical development and translational medicine functions. Dr. Stein also previously played a pivotal role in bringing several products to the market including Sustiva®, Fablyn®, Viviant®, PanRetin®, TargRetin®, Promacta® and Eliquis®. He has also held executive management positions at Ligand Pharmaceuticals, DuPont Merck, Incyte Pharmaceuticals, Roche Palo Alto and KineMed. Dr. Stein holds an MD and a PhD in Physiology & Pharmacology from Duke University.

Tom Harrison, Chairman Emeritus of Diversified Agency Services (DAS) at Omnicom Group, transformed DAS into Omnicom’s largest division with over $6 billion in annual revenue and more than 5000 clients. Co-founder of Harrison & Star, a leading healthcare advertising agency, Harrison’s innovative approach merged science with creativity. He currently serves as Senior Operating Partner at Merida Capital Partners, focusing on strategic advising in the cannabis industry. Harrison’s appointment to the Agenus Board of Directors brings invaluable expertise in healthcare advertising and strategic communications, essential for elevating Agenus’ global visibility and advancing its immunotherapy pipeline. Harrison holds an Honorary Doctorate from West Virginia University and authored “INSTINCT.”

Mr. Timothy Wright is the Chief Executive Officer of MiMedX Group, Inc., a position that he has held since May 2019. MiMedX is an advanced wound care and emerging therapeutic biologics company. Mr. Wright also serves as a Partner at Signal Hill Advisors, LLC, a position he has held since February 2011. In addition, Mr. Wright serves as Chairman of The Ohio State University Comprehensive Cancer Center Drug Development Institute and Director of the Ohio State University Innovation Foundation. Mr. Wright previously held several executive roles at Covidien (now Medtronic), Teva Pharmaceuticals Industries Ltd., DuPont Merck, Elan Bio-Pharmaceuticals, M2Gen Corp. and Curaxis Pharmaceuticals Corporation. As our Lead Director, Mr. Wright brings 30 years of experience on boards of companies in North America, Europe, Asia and Japan.

Ms. Susan Hirsch has over 40 years of experience in investment management and finance, including her most recent position as a Managing Director at Nuveen, a TIAA company, where she was responsible for Nuveen’s TIAA-CREF Large-Cap Growth Fund with $6.6 billion in assets. Prior to joining Nuveen in 2005, she served as Executive Vice President at Jennison Associates. Ms. Hirsch’s previous experience also includes investment management positions at Lehman Brothers Global Asset Management and Delphi Asset Management. She began her career as an analyst at Smith Barney and Lehman Brothers, where the success of her quantitative model for small-cap growth stocks led to her subsequent investment management positions. Ms. Hirsch holds a BS in Accounting from Brooklyn College.

Mr. Corvese is president and founder of Vencor Capital, a private equity firm with telecommunications and technology investments in the Middle East and Mediterranean regions. Prior to Vencor, Mr. Corvese worked on investments in the US and global equity markets as a managing director and partner at Soros Fund Management, the largest hedge fund in the world at the time. From 1988 to 1996, Mr. Corvese was a partner at Chancellor Capital Management, a $25-billion money management firm. While at Chancellor, Mr. Corvese was a portfolio manager with responsibility for investments made in basic industries, restructurings, and special situations, corporate governance investments, as well as founding and managing his own hedge fund. From 1981 to 1988, Mr. Corvese was with Drexel Burnham Lambert as an equity analyst following the chemical and specialty chemical industries and he participated in a significant number of merger and acquisition activities. While at Drexel, Mr. Corvese was a member of the top chemical and specialty chemical research team, as ranked by Institutional Investor. Mr. Corvese currently serves on the board of the National Telecommunications Company, based in Cairo, Egypt. Mr. Corvese earned degrees in finance and political science from The University of Rhode Island and attended New York University Graduate School.

Dr. José Iglesias brings more than 30 years of global experience in oncology and immuno-oncology drug development to Agenus. Most recently, he held senior medical leadership roles at Bionomics, Biothera, and Apobiologix, where he directed global oncology programs spanning biologics, small molecules, and immunotherapies.

Earlier in his career, Dr. Iglesias served as Chief Medical Officer and Senior Vice President at Abraxis BioScience, where he led worldwide development of Abraxane and other oncology assets, and as Vice President of Clinical Development at Celgene, guiding late-stage programs in pancreatic, lung, and metastatic breast cancers that established Abraxane as a global standard of care. He also held medical and clinical development leadership roles at Eli Lilly (in Canada and Australia), where he helped shape the company’s oncology portfolio across the Asia-Pacific region.

An author of more than 70 peer-reviewed oncology publications, Dr. Iglesias is widely recognized in the global oncology community and maintains strong collaborations with regulatory agencies, cooperative groups, and patient advocacy organizations. He earned his medical degree in Uruguay and completed fellowships at the Weizmann Institute of Science, Duke University, and the University of Toronto. He is an active member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), and the European Society for Medical Oncology (ESMO).

Zack is responsible for Investor Relations and Corporate Development activities at Agenus.  Previously, Zack was Director of Corporate Development at Valo Health, where he led several in-licensing and M&A efforts, including the company’s acquisition of Courier Therapeutics. Prior to Valo he spent several years at Flagship Pioneering where he helped found multiple new ventures created by the company, including Head of Corporate Development at CiBO Technologies. He earned his MBA at MIT Sloan, prior to which he was at Goldman Sachs & Co where he served as an analyst and associate on the business management team for the Private Banking unit. He holds a B.A. degree from Johns Hopkins University where he also played basketball on the Men’s Varsity team.

Craig Winter serves as the Chief Information Officer, responsible for overseeing data management, IT strategy and operations across all areas of Agenus. Craig has over 30 years of experience in transforming organizations and enhancing their business efficiency by building and supporting their IT infrastructure. Prior to joining Agenus, Craig was the President and Founder of Teracom Networks. Craig has a B.S. in Economics and Business Administration from Albright College.

Dr. Richard M. Goldberg serves as the Chief Development Officer at Agenus. An internationally recognized leader in gastrointestinal (GI) cancer treatment and research, Dr. Goldberg brings more than four decades of experience in academic oncology and cancer program leadership. Before joining Agenus, Dr. Goldberg served as Director of the West Virginia University Cancer Institute (WVUCI), overseeing its clinical, research, and educational missions. He was also a member of the leadership team for the WVU Health Sciences Center. Prior to WVU, he held senior leadership roles at top cancer centers, including Physician-in-Chief at both The Ohio State University’s James Cancer Hospital and the North Carolina Cancer Hospital at the University of North Carolina in Chapel Hill. He also served as Associate Director at the comprehensive cancer centers at both institutions and held division chief roles in hematology and oncology.

Throughout his career, Dr. Goldberg has been principal investigator, co-investigator, and mentor on numerous research and training grants funded by the National Cancer Institute. He has authored more than 320 peer-reviewed publications and is a frequent invited speaker at scientific conferences and academic institutions worldwide.

Dr. Goldberg earned his undergraduate degree cum laude in biology from Harvard University and received his medical degree from SUNY Upstate Medical University.

Robin Taylor, Ph.D. serves as the Chief Commercial Officer at Agenus, leading the commercial team and strategy, drawing on his extensive oncology global development and commercialization experience. His most recent leadership position was in the role of Chief Commercial Officer at Seagen, Inc. where he led the Commercial organization through a period of significant growth in preparation for the launches of PADCEV® (enfortumab vedotin), and TUKYSA® (tucatinib). Prior to this role Dr. Taylor was the Immuno-Oncology Franchise Head in the Oncology Business Unit at AstraZeneca, where he led the global medicine and product teams responsible for IMFINZI® (durvalumab), and IMJUDO® (tremelimumab). Robin spent the greatest part of his career in commercial roles of increasing responsibility at Genentech, a Member of the Roche Group, ultimately serving as the Lung and Cancer Immunotherapy Franchise Head, Global Product Strategy, responsible for the global development and commercialization of ALECENSA® (alectinib) and TECENTRIQ® (atezolizumab) across multiple indications.

Robin holds a Doctor of Philosophy in Molecular and Medical Genetics from University of Toronto, a Master of Business Administration from University of California Berkeley, and a Bachelor of Science from University of British Columbia.

Stefanie Perna-Nacar is a seasoned executive with over 20 years of experience in marketing, communications, digital strategy, and public relations within the pharmaceutical industry. She excels at building brands, leading strategic communications, and driving business impact across global and U.S. markets.

Her expertise spans all phases of product development, from early pipeline to commercialization and lifecycle management. She has successfully launched and repositioned brands through innovative campaigns, omni-channel engagement, and high-impact PR initiatives. Having held leadership roles in both multinational corporations and biotech startups, she consistently delivers strategies that strengthen corporate reputation and stakeholder engagement.

As Head of U.S. Oncology Communications & Public Relations at GSK, Stefanie led all internal and external communications, developing award-winning PR and digital engagement campaigns that expanded brand adoption and set new corporate benchmarks. At TESARO Pharmaceuticals, she built and led the company’s marketing communications and digital strategy functions, spearheading multi-channel PR campaigns, including celebrity-driven initiatives.

Beyond communications, Stefanie has deep expertise in commercial strategy, serving as Vice President of Marketing at MorphoSys Pharmaceuticals and holding senior marketing and new product planning roles at Merck KGaA/EMD Serono, Infinity Pharmaceuticals, and Sanofi.

Her work has earned MM&M’s Marketer of the Year, PM360 Trailblazer Awards, and multiple DTC Ad Awards for excellence in brand strategy, public relations, and communications.

She holds a B.S. in Communications from Ohio University and is recognized for her strategic vision, innovative leadership, and ability to align marketing and communications to drive business success.

Dr. Steven O’Day serves as Agenus’ Chief Medical Officer. He is responsible for leading the expansion of the company’s presence in the I-O field. A pioneer in CTLA-4 inhibition, Steven played key roles in the advancement of cancer therapies Yervoy and Opdivo, and has been the principal investigator in more than 200 clinical trials. Prior to joining Agenus, he was Executive Director of the John Wayne Cancer Institute and Cancer Clinics at Providence St. John’s Health Center, and Director of the Melanoma and Cutaneous Oncology Research Center. Steven was a visiting scholar in philosophy and medical ethics at Oxford, received his MD from Johns Hopkins, and was a Fellow at the Dana Farber/Harvard Cancer Center.

Alfred Dadson serves as Chief Manufacturing Officer in our Global Biologics Operations. Al is responsible for process development of our antibodies, vaccines, and cell therapies, from manufacturing through to commercialization. Previously, he was Vice President of Antibody Manufacturing Operations and Site Head of Agenus West, leading the team who developed a record number of eight antibody programs through to successful IND acceptance in under two years. Prior to joining Agenus, Al was Vice President of Manufacturing Operations and Facilities Engineering at XOMA. Al holds a patent on a state-of-the-art modular facility design and was named a lifetime member of Industry Leaders’ Who is Who by his peers.

Tracy Mazza Clemente serves as the Chief People Officer, holding prior positions as Head of Talent Acquisition and Global Head of HR. As the architect of the Agenus Talent Strategy, Tracy leads Agenus’ mission to discover and inspire the world’s greatest minds. By cultivating a workplace ethos of curiosity and ambition, Tracy empowers employees to harness their full potential and radically innovate on behalf of patients everywhere. Previously, Tracy led the US Scientific Talent Acquisition practice at Randstad. She holds a BA in Government and International Relations from Saint Mary’s College in Moraga, CA.

Dr. Jennifer Buell is the President and Chief Executive Officer at MiNK Therapeutics and the Chairman, Executive Council at Agenus. She brings more than 27 years of biopharmaceutical experience, leading teams to advance discovery candidates through to clinical development to commercialization. She was previously President and Chief Operating Officer at Agenus, where she was responsible for organizational operations, including research, clinical development, manufacturing, commercial operations, investor relations and external affairs. During her tenure, she transformed Agenus from a single-product company to a global, fully-integrated biotech company with multiple strategic partnerships. Prior to Agenus, Dr. Buell held leadership positions in R&D operations at Bristol-Myers Squibb and Harvard Clinical Research Institute (Baim), where she was involved in the development strategy and operations for a portfolio of industry and government-sponsored clinical programs. She obtained her Ph.D. in Cellular, Biochemical, and Molecular Biochemistry with an M.S. in Biostatistics from Tufts University.

Dr. Garo Armen serves as Chairman and Chief Executive Officer of Agenus Inc., which he co-founded in 1994. Under his leadership, Agenus has been advancing breakthrough scientific technologies and immunotherapeutic products. In addition, Garo oversaw the successful restructuring of the biopharmaceutical company Elan Corporation, plc, where he served as Chairman of the Board of Directors. Garo currently acts as Chairman of the Board of Protagenic Therapeutics, a biotechnology company focusing on human brain hormones for the treatment of neurological and metabolic disorders. He began his research career at Brookhaven National Laboratory subsequent to which he made a transition to Wall Street, as an analyst and investment banker at EF Hutton and then at Dean Witter Reynolds (now Morgan Stanley), cultivating key relationships and stock-market expertise. Garo received his PhD in physical chemistry from the City University of New York.